Me Medicine vs. We Medicine: Reclaiming Biotechnology for the Common Good
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
New York, NY
Columbia University Press
[2013]
|
| Schlagworte: | |
| Online-Zugang: | FAB01 FAW01 FCO01 FHA01 FKE01 FLA01 UBG01 UPA01 Volltext |
| Beschreibung: | Description based on online resource; title from PDF title page (publisher’s Web site, viewed September 10 2015) |
| Beschreibung: | 1 online resource (296 pages) illustrations |
| ISBN: | 9780231534413 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV042999392 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 151111s2013 |||| o||u| ||||||eng d | ||
| 020 | |a 9780231534413 |9 978-0-231-53441-3 | ||
| 024 | 7 | |a 10.7312/dick15974 |2 doi | |
| 035 | |a (OCoLC)1165489453 | ||
| 035 | |a (DE-599)BVBBV042999392 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-859 |a DE-860 |a DE-473 |a DE-Aug4 |a DE-739 |a DE-1046 |a DE-1043 |a DE-858 | ||
| 082 | 0 | |a 174.2 |2 23 | |
| 100 | 1 | |a Dickenson, Donna |4 aut | |
| 245 | 1 | 0 | |a Me Medicine vs. We Medicine |b Reclaiming Biotechnology for the Common Good |c Donna Dickenson |
| 264 | 1 | |a New York, NY |b Columbia University Press |c [2013] | |
| 264 | 4 | |c © 2013 | |
| 300 | |a 1 online resource (296 pages) |b illustrations | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Description based on online resource; title from PDF title page (publisher’s Web site, viewed September 10 2015) | ||
| 505 | 8 | |a Personalized healthcare--or what the award-winning author Donna Dickenson calls "Me Medicine"--is radically transforming our longstanding "one-size-fits-all" model. Technologies such as direct-to-consumer genetic testing, pharmacogenetically developed therapies in cancer care, private umbilical cord blood banking, and neurocognitive enhancement claim to cater to an individual's specific biological character, and, in some cases, these technologies have shown powerful potential. Yet in others they have produced negligible or even negative results. Whatever is behind the rise of Me Medicine, it isn't just science. | |
| 505 | 8 | |a So why is Me Medicine rapidly edging out We Medicine, and how has our commitment to our collective health suffered as a result? In her cogent, provocative analysis, Dickenson examines the economic and political factors fueling the Me Medicine phenomenon and explores how, over time, this paradigm shift in how we approach our health might damage our individual and collective well-being. Historically, the measures of "We Medicine," such as vaccination and investment in public-health infrastructure, have radically extended our life spans, and Dickenson argues we've lost sight of that truth in our enthusiasm for "Me Medicine." Dickenson explores how personalized medicine illustrates capitalism's protean capacity for creating new products and markets where none existed before--and how this, rather than scientific plausibility, goes a long way toward explaining private umbilical cord blood banks and retail genetics. | |
| 505 | 8 | |a Drawing on the latest findings from leading scientists, social scientists, and political analysts, she critically examines four possible hypotheses driving our Me Medicine moment: a growing sense of threat; a wave of patient narcissism; corporate interests driving new niche markets; and the dominance of personal choice as a cultural value. She concludes with insights from political theory that emphasize a conception of the commons and the steps we can take to restore its value to modern biotechnology | |
| 546 | |a In English | ||
| 650 | 4 | |a Philosophie | |
| 650 | 4 | |a Social Justice | |
| 650 | 7 | |a MEDICAL / Ethics |2 bisacsh | |
| 650 | 7 | |a SCIENCE / Applied Sciences |2 bisacsh | |
| 650 | 4 | |a Ethik | |
| 650 | 4 | |a Medizin | |
| 650 | 4 | |a Biotechnology |x ethics | |
| 650 | 4 | |a Biotechnology |x Moral and ethical aspects | |
| 650 | 4 | |a Individualized Medicine |x ethics | |
| 650 | 4 | |a Medicine, Preventive |x Moral and ethical aspects | |
| 650 | 4 | |a Patient-centered health care |x Moral and ethical aspects | |
| 650 | 4 | |a Public Health Practice |x ethics | |
| 650 | 0 | 7 | |a Ethik |0 (DE-588)4015602-3 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Biotechnologie |0 (DE-588)4069491-4 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Gesundheitswesen |0 (DE-588)4020775-4 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Medizinische Ethik |0 (DE-588)4074672-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Individualisierte Medizin |0 (DE-588)7660544-9 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Individualisierte Medizin |0 (DE-588)7660544-9 |D s |
| 689 | 0 | 1 | |a Medizinische Ethik |0 (DE-588)4074672-0 |D s |
| 689 | 0 | |8 1\p |5 DE-604 | |
| 689 | 1 | 0 | |a Biotechnologie |0 (DE-588)4069491-4 |D s |
| 689 | 1 | 1 | |a Ethik |0 (DE-588)4015602-3 |D s |
| 689 | 1 | |8 2\p |5 DE-604 | |
| 689 | 2 | 0 | |a Gesundheitswesen |0 (DE-588)4020775-4 |D s |
| 689 | 2 | 1 | |a Ethik |0 (DE-588)4015602-3 |D s |
| 689 | 2 | |8 3\p |5 DE-604 | |
| 856 | 4 | 0 | |u http://www.degruyter.com/doi/book/10.7312/dick15974 |x Verlag |3 Volltext |
| 912 | |a ZDB-23-DGG | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-028424643 | ||
| 883 | 1 | |8 1\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 883 | 1 | |8 2\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 883 | 1 | |8 3\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 966 | e | |u http://www.degruyter.com/doi/book/10.7312/dick15974 |l FAB01 |p ZDB-23-DGG |x Verlag |3 Volltext | |
| 966 | e | |u http://www.degruyter.com/doi/book/10.7312/dick15974 |l FAW01 |p ZDB-23-DGG |q FAW_PDA_DGG |x Verlag |3 Volltext | |
| 966 | e | |u http://www.degruyter.com/doi/book/10.7312/dick15974 |l FCO01 |p ZDB-23-DGG |q FCO_PDA_DGG |x Verlag |3 Volltext | |
| 966 | e | |u http://www.degruyter.com/doi/book/10.7312/dick15974 |l FHA01 |p ZDB-23-DGG |q FHA_PDA_DGG |x Verlag |3 Volltext | |
| 966 | e | |u http://www.degruyter.com/doi/book/10.7312/dick15974 |l FKE01 |p ZDB-23-DGG |q FKE_PDA_DGG |x Verlag |3 Volltext | |
| 966 | e | |u http://www.degruyter.com/doi/book/10.7312/dick15974 |l FLA01 |p ZDB-23-DGG |q FLA_PDA_DGG |x Verlag |3 Volltext | |
| 966 | e | |u http://www.degruyter.com/doi/book/10.7312/dick15974 |l UBG01 |p ZDB-23-DGG |q UBG_PDA_DGG |x Verlag |3 Volltext | |
| 966 | e | |u http://www.degruyter.com/doi/book/10.7312/dick15974 |l UPA01 |p ZDB-23-DGG |q UPA_PDA_DGG |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804175338711810048 |
|---|---|
| any_adam_object | |
| author | Dickenson, Donna |
| author_facet | Dickenson, Donna |
| author_role | aut |
| author_sort | Dickenson, Donna |
| author_variant | d d dd |
| building | Verbundindex |
| bvnumber | BV042999392 |
| collection | ZDB-23-DGG |
| contents | Personalized healthcare--or what the award-winning author Donna Dickenson calls "Me Medicine"--is radically transforming our longstanding "one-size-fits-all" model. Technologies such as direct-to-consumer genetic testing, pharmacogenetically developed therapies in cancer care, private umbilical cord blood banking, and neurocognitive enhancement claim to cater to an individual's specific biological character, and, in some cases, these technologies have shown powerful potential. Yet in others they have produced negligible or even negative results. Whatever is behind the rise of Me Medicine, it isn't just science. So why is Me Medicine rapidly edging out We Medicine, and how has our commitment to our collective health suffered as a result? In her cogent, provocative analysis, Dickenson examines the economic and political factors fueling the Me Medicine phenomenon and explores how, over time, this paradigm shift in how we approach our health might damage our individual and collective well-being. Historically, the measures of "We Medicine," such as vaccination and investment in public-health infrastructure, have radically extended our life spans, and Dickenson argues we've lost sight of that truth in our enthusiasm for "Me Medicine." Dickenson explores how personalized medicine illustrates capitalism's protean capacity for creating new products and markets where none existed before--and how this, rather than scientific plausibility, goes a long way toward explaining private umbilical cord blood banks and retail genetics. Drawing on the latest findings from leading scientists, social scientists, and political analysts, she critically examines four possible hypotheses driving our Me Medicine moment: a growing sense of threat; a wave of patient narcissism; corporate interests driving new niche markets; and the dominance of personal choice as a cultural value. She concludes with insights from political theory that emphasize a conception of the commons and the steps we can take to restore its value to modern biotechnology |
| ctrlnum | (OCoLC)1165489453 (DE-599)BVBBV042999392 |
| dewey-full | 174.2 |
| dewey-hundreds | 100 - Philosophy & psychology |
| dewey-ones | 174 - Occupational ethics |
| dewey-raw | 174.2 |
| dewey-search | 174.2 |
| dewey-sort | 3174.2 |
| dewey-tens | 170 - Ethics (Moral philosophy) |
| discipline | Philosophie |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>05755nmm a2200817zc 4500</leader><controlfield tag="001">BV042999392</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">151111s2013 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780231534413</subfield><subfield code="9">978-0-231-53441-3</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.7312/dick15974</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1165489453</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV042999392</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-859</subfield><subfield code="a">DE-860</subfield><subfield code="a">DE-473</subfield><subfield code="a">DE-Aug4</subfield><subfield code="a">DE-739</subfield><subfield code="a">DE-1046</subfield><subfield code="a">DE-1043</subfield><subfield code="a">DE-858</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">174.2</subfield><subfield code="2">23</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Dickenson, Donna</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Me Medicine vs. We Medicine</subfield><subfield code="b">Reclaiming Biotechnology for the Common Good</subfield><subfield code="c">Donna Dickenson</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York, NY</subfield><subfield code="b">Columbia University Press</subfield><subfield code="c">[2013]</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">© 2013</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (296 pages)</subfield><subfield code="b">illustrations</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Description based on online resource; title from PDF title page (publisher’s Web site, viewed September 10 2015)</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Personalized healthcare--or what the award-winning author Donna Dickenson calls "Me Medicine"--is radically transforming our longstanding "one-size-fits-all" model. Technologies such as direct-to-consumer genetic testing, pharmacogenetically developed therapies in cancer care, private umbilical cord blood banking, and neurocognitive enhancement claim to cater to an individual's specific biological character, and, in some cases, these technologies have shown powerful potential. Yet in others they have produced negligible or even negative results. Whatever is behind the rise of Me Medicine, it isn't just science. </subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">So why is Me Medicine rapidly edging out We Medicine, and how has our commitment to our collective health suffered as a result? In her cogent, provocative analysis, Dickenson examines the economic and political factors fueling the Me Medicine phenomenon and explores how, over time, this paradigm shift in how we approach our health might damage our individual and collective well-being. Historically, the measures of "We Medicine," such as vaccination and investment in public-health infrastructure, have radically extended our life spans, and Dickenson argues we've lost sight of that truth in our enthusiasm for "Me Medicine." Dickenson explores how personalized medicine illustrates capitalism's protean capacity for creating new products and markets where none existed before--and how this, rather than scientific plausibility, goes a long way toward explaining private umbilical cord blood banks and retail genetics. </subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Drawing on the latest findings from leading scientists, social scientists, and political analysts, she critically examines four possible hypotheses driving our Me Medicine moment: a growing sense of threat; a wave of patient narcissism; corporate interests driving new niche markets; and the dominance of personal choice as a cultural value. She concludes with insights from political theory that emphasize a conception of the commons and the steps we can take to restore its value to modern biotechnology</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">In English</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Philosophie</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Social Justice</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Ethics</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SCIENCE / Applied Sciences</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ethik</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medizin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biotechnology</subfield><subfield code="x">ethics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biotechnology</subfield><subfield code="x">Moral and ethical aspects</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Individualized Medicine</subfield><subfield code="x">ethics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medicine, Preventive</subfield><subfield code="x">Moral and ethical aspects</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Patient-centered health care</subfield><subfield code="x">Moral and ethical aspects</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Public Health Practice</subfield><subfield code="x">ethics</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Ethik</subfield><subfield code="0">(DE-588)4015602-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Biotechnologie</subfield><subfield code="0">(DE-588)4069491-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Gesundheitswesen</subfield><subfield code="0">(DE-588)4020775-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Medizinische Ethik</subfield><subfield code="0">(DE-588)4074672-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Individualisierte Medizin</subfield><subfield code="0">(DE-588)7660544-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Individualisierte Medizin</subfield><subfield code="0">(DE-588)7660544-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Medizinische Ethik</subfield><subfield code="0">(DE-588)4074672-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="8">1\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Biotechnologie</subfield><subfield code="0">(DE-588)4069491-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Ethik</subfield><subfield code="0">(DE-588)4015602-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="8">2\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="2" ind2="0"><subfield code="a">Gesundheitswesen</subfield><subfield code="0">(DE-588)4020775-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2="1"><subfield code="a">Ethik</subfield><subfield code="0">(DE-588)4015602-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2=" "><subfield code="8">3\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.degruyter.com/doi/book/10.7312/dick15974</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-23-DGG</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-028424643</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">2\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">3\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://www.degruyter.com/doi/book/10.7312/dick15974</subfield><subfield code="l">FAB01</subfield><subfield code="p">ZDB-23-DGG</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://www.degruyter.com/doi/book/10.7312/dick15974</subfield><subfield code="l">FAW01</subfield><subfield code="p">ZDB-23-DGG</subfield><subfield code="q">FAW_PDA_DGG</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://www.degruyter.com/doi/book/10.7312/dick15974</subfield><subfield code="l">FCO01</subfield><subfield code="p">ZDB-23-DGG</subfield><subfield code="q">FCO_PDA_DGG</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://www.degruyter.com/doi/book/10.7312/dick15974</subfield><subfield code="l">FHA01</subfield><subfield code="p">ZDB-23-DGG</subfield><subfield code="q">FHA_PDA_DGG</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://www.degruyter.com/doi/book/10.7312/dick15974</subfield><subfield code="l">FKE01</subfield><subfield code="p">ZDB-23-DGG</subfield><subfield code="q">FKE_PDA_DGG</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://www.degruyter.com/doi/book/10.7312/dick15974</subfield><subfield code="l">FLA01</subfield><subfield code="p">ZDB-23-DGG</subfield><subfield code="q">FLA_PDA_DGG</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://www.degruyter.com/doi/book/10.7312/dick15974</subfield><subfield code="l">UBG01</subfield><subfield code="p">ZDB-23-DGG</subfield><subfield code="q">UBG_PDA_DGG</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://www.degruyter.com/doi/book/10.7312/dick15974</subfield><subfield code="l">UPA01</subfield><subfield code="p">ZDB-23-DGG</subfield><subfield code="q">UPA_PDA_DGG</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV042999392 |
| illustrated | Illustrated |
| indexdate | 2024-07-10T07:14:42Z |
| institution | BVB |
| isbn | 9780231534413 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-028424643 |
| oclc_num | 1165489453 |
| open_access_boolean | |
| owner | DE-859 DE-860 DE-473 DE-BY-UBG DE-Aug4 DE-739 DE-1046 DE-1043 DE-858 |
| owner_facet | DE-859 DE-860 DE-473 DE-BY-UBG DE-Aug4 DE-739 DE-1046 DE-1043 DE-858 |
| physical | 1 online resource (296 pages) illustrations |
| psigel | ZDB-23-DGG ZDB-23-DGG FAW_PDA_DGG ZDB-23-DGG FCO_PDA_DGG ZDB-23-DGG FHA_PDA_DGG ZDB-23-DGG FKE_PDA_DGG ZDB-23-DGG FLA_PDA_DGG ZDB-23-DGG UBG_PDA_DGG ZDB-23-DGG UPA_PDA_DGG |
| publishDate | 2013 |
| publishDateSearch | 2013 |
| publishDateSort | 2013 |
| publisher | Columbia University Press |
| record_format | marc |
| spelling | Dickenson, Donna aut Me Medicine vs. We Medicine Reclaiming Biotechnology for the Common Good Donna Dickenson New York, NY Columbia University Press [2013] © 2013 1 online resource (296 pages) illustrations txt rdacontent c rdamedia cr rdacarrier Description based on online resource; title from PDF title page (publisher’s Web site, viewed September 10 2015) Personalized healthcare--or what the award-winning author Donna Dickenson calls "Me Medicine"--is radically transforming our longstanding "one-size-fits-all" model. Technologies such as direct-to-consumer genetic testing, pharmacogenetically developed therapies in cancer care, private umbilical cord blood banking, and neurocognitive enhancement claim to cater to an individual's specific biological character, and, in some cases, these technologies have shown powerful potential. Yet in others they have produced negligible or even negative results. Whatever is behind the rise of Me Medicine, it isn't just science. So why is Me Medicine rapidly edging out We Medicine, and how has our commitment to our collective health suffered as a result? In her cogent, provocative analysis, Dickenson examines the economic and political factors fueling the Me Medicine phenomenon and explores how, over time, this paradigm shift in how we approach our health might damage our individual and collective well-being. Historically, the measures of "We Medicine," such as vaccination and investment in public-health infrastructure, have radically extended our life spans, and Dickenson argues we've lost sight of that truth in our enthusiasm for "Me Medicine." Dickenson explores how personalized medicine illustrates capitalism's protean capacity for creating new products and markets where none existed before--and how this, rather than scientific plausibility, goes a long way toward explaining private umbilical cord blood banks and retail genetics. Drawing on the latest findings from leading scientists, social scientists, and political analysts, she critically examines four possible hypotheses driving our Me Medicine moment: a growing sense of threat; a wave of patient narcissism; corporate interests driving new niche markets; and the dominance of personal choice as a cultural value. She concludes with insights from political theory that emphasize a conception of the commons and the steps we can take to restore its value to modern biotechnology In English Philosophie Social Justice MEDICAL / Ethics bisacsh SCIENCE / Applied Sciences bisacsh Ethik Medizin Biotechnology ethics Biotechnology Moral and ethical aspects Individualized Medicine ethics Medicine, Preventive Moral and ethical aspects Patient-centered health care Moral and ethical aspects Public Health Practice ethics Ethik (DE-588)4015602-3 gnd rswk-swf Biotechnologie (DE-588)4069491-4 gnd rswk-swf Gesundheitswesen (DE-588)4020775-4 gnd rswk-swf Medizinische Ethik (DE-588)4074672-0 gnd rswk-swf Individualisierte Medizin (DE-588)7660544-9 gnd rswk-swf Individualisierte Medizin (DE-588)7660544-9 s Medizinische Ethik (DE-588)4074672-0 s 1\p DE-604 Biotechnologie (DE-588)4069491-4 s Ethik (DE-588)4015602-3 s 2\p DE-604 Gesundheitswesen (DE-588)4020775-4 s 3\p DE-604 http://www.degruyter.com/doi/book/10.7312/dick15974 Verlag Volltext 1\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk 2\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk 3\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk |
| spellingShingle | Dickenson, Donna Me Medicine vs. We Medicine Reclaiming Biotechnology for the Common Good Personalized healthcare--or what the award-winning author Donna Dickenson calls "Me Medicine"--is radically transforming our longstanding "one-size-fits-all" model. Technologies such as direct-to-consumer genetic testing, pharmacogenetically developed therapies in cancer care, private umbilical cord blood banking, and neurocognitive enhancement claim to cater to an individual's specific biological character, and, in some cases, these technologies have shown powerful potential. Yet in others they have produced negligible or even negative results. Whatever is behind the rise of Me Medicine, it isn't just science. So why is Me Medicine rapidly edging out We Medicine, and how has our commitment to our collective health suffered as a result? In her cogent, provocative analysis, Dickenson examines the economic and political factors fueling the Me Medicine phenomenon and explores how, over time, this paradigm shift in how we approach our health might damage our individual and collective well-being. Historically, the measures of "We Medicine," such as vaccination and investment in public-health infrastructure, have radically extended our life spans, and Dickenson argues we've lost sight of that truth in our enthusiasm for "Me Medicine." Dickenson explores how personalized medicine illustrates capitalism's protean capacity for creating new products and markets where none existed before--and how this, rather than scientific plausibility, goes a long way toward explaining private umbilical cord blood banks and retail genetics. Drawing on the latest findings from leading scientists, social scientists, and political analysts, she critically examines four possible hypotheses driving our Me Medicine moment: a growing sense of threat; a wave of patient narcissism; corporate interests driving new niche markets; and the dominance of personal choice as a cultural value. She concludes with insights from political theory that emphasize a conception of the commons and the steps we can take to restore its value to modern biotechnology Philosophie Social Justice MEDICAL / Ethics bisacsh SCIENCE / Applied Sciences bisacsh Ethik Medizin Biotechnology ethics Biotechnology Moral and ethical aspects Individualized Medicine ethics Medicine, Preventive Moral and ethical aspects Patient-centered health care Moral and ethical aspects Public Health Practice ethics Ethik (DE-588)4015602-3 gnd Biotechnologie (DE-588)4069491-4 gnd Gesundheitswesen (DE-588)4020775-4 gnd Medizinische Ethik (DE-588)4074672-0 gnd Individualisierte Medizin (DE-588)7660544-9 gnd |
| subject_GND | (DE-588)4015602-3 (DE-588)4069491-4 (DE-588)4020775-4 (DE-588)4074672-0 (DE-588)7660544-9 |
| title | Me Medicine vs. We Medicine Reclaiming Biotechnology for the Common Good |
| title_auth | Me Medicine vs. We Medicine Reclaiming Biotechnology for the Common Good |
| title_exact_search | Me Medicine vs. We Medicine Reclaiming Biotechnology for the Common Good |
| title_full | Me Medicine vs. We Medicine Reclaiming Biotechnology for the Common Good Donna Dickenson |
| title_fullStr | Me Medicine vs. We Medicine Reclaiming Biotechnology for the Common Good Donna Dickenson |
| title_full_unstemmed | Me Medicine vs. We Medicine Reclaiming Biotechnology for the Common Good Donna Dickenson |
| title_short | Me Medicine vs. We Medicine |
| title_sort | me medicine vs we medicine reclaiming biotechnology for the common good |
| title_sub | Reclaiming Biotechnology for the Common Good |
| topic | Philosophie Social Justice MEDICAL / Ethics bisacsh SCIENCE / Applied Sciences bisacsh Ethik Medizin Biotechnology ethics Biotechnology Moral and ethical aspects Individualized Medicine ethics Medicine, Preventive Moral and ethical aspects Patient-centered health care Moral and ethical aspects Public Health Practice ethics Ethik (DE-588)4015602-3 gnd Biotechnologie (DE-588)4069491-4 gnd Gesundheitswesen (DE-588)4020775-4 gnd Medizinische Ethik (DE-588)4074672-0 gnd Individualisierte Medizin (DE-588)7660544-9 gnd |
| topic_facet | Philosophie Social Justice MEDICAL / Ethics SCIENCE / Applied Sciences Ethik Medizin Biotechnology ethics Biotechnology Moral and ethical aspects Individualized Medicine ethics Medicine, Preventive Moral and ethical aspects Patient-centered health care Moral and ethical aspects Public Health Practice ethics Biotechnologie Gesundheitswesen Medizinische Ethik Individualisierte Medizin |
| url | http://www.degruyter.com/doi/book/10.7312/dick15974 |
| work_keys_str_mv | AT dickensondonna memedicinevswemedicinereclaimingbiotechnologyforthecommongood |